Literature DB >> 22789708

Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.

Wei Wang1, Haiping Cao, Siglinde Wolf, Miguel S Camacho-Horvitz, Tad A Holak, Alexander Dömling.   

Abstract

Herein we propose the benzimidazole-2-one substructure as a suitable tryptophan mimic and thus a reasonable starting point for the design of p53 Mdm2 antagonists. We devise a short multicomponent reaction route to hitherto unknown 2-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetamides by reacting mono N-carbamate protected phenylenediamine in a Ugi-3CR followed by base induced cyclisation. Our preliminary synthesis and screening results are presented here. The finding of the benzimidazolone moiety as a tryptophan replacement in mdm2 is significant as it offers access to novel scaffolds with potentially higher selectivity and potency and improved biological activities. Observing low μM affinities to mdm2 by NMR and fluorescence polarization we conclude that the 2-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetamide scaffold might be a good starting point to further optimize the affinities to Mdm2.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22789708      PMCID: PMC3716288          DOI: 10.1016/j.bmc.2012.06.020

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  45 in total

1.  NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro.

Authors:  Marcin Krajewski; Przemyslaw Ozdowy; Loyola D'Silva; Ulli Rothweiler; Tad A Holak
Journal:  Nat Med       Date:  2005-11       Impact factor: 53.440

2.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.

Authors:  Grzegorz M Popowicz; Anna Czarna; Tad A Holak
Journal:  Cell Cycle       Date:  2008-05-27       Impact factor: 4.534

3.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.

Authors:  Anna Czarna; Grzegorz M Popowicz; Aleksandra Pecak; Siglinde Wolf; Grzegorz Dubin; Tad A Holak
Journal:  Cell Cycle       Date:  2009-04-16       Impact factor: 4.534

4.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 5.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Authors:  Grzegorz M Popowicz; Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-21       Impact factor: 15.336

6.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

7.  Adamantane 11-beta-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction.

Authors:  Bryan Sorensen; Jeff Rohde; Jiahong Wang; Steven Fung; Katina Monzon; William Chiou; Liping Pan; Xiaoqing Deng; DeAnne Stolarik; Ernst U Frevert; Peer Jacobson; J T Link
Journal:  Bioorg Med Chem Lett       Date:  2006-09-25       Impact factor: 2.823

8.  Robust NMR screening for lead compounds using tryptophan-containing proteins.

Authors:  Michal Bista; Kaja Kowalska; Weronika Janczyk; Alexander Dömling; Tad A Holak
Journal:  J Am Chem Soc       Date:  2009-06-10       Impact factor: 15.419

Review 9.  Rational approaches to improving selectivity in drug design.

Authors:  David J Huggins; Woody Sherman; Bruce Tidor
Journal:  J Med Chem       Date:  2012-01-12       Impact factor: 7.446

Review 10.  Targeting the cancer kinome through polypharmacology.

Authors:  Zachary A Knight; Henry Lin; Kevan M Shokat
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

View more
  3 in total

1.  Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists.

Authors:  S Shaabani; C G Neochoritis; A Twarda-Clapa; B Musielak; T A Holak; A Dömling
Journal:  Medchemcomm       Date:  2017-03-15       Impact factor: 3.597

2.  Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.

Authors:  Edwin Kroon; Jörg O Schulze; Evelyn Süß; Carlos J Camacho; Ricardo M Biondi; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2015-09-04       Impact factor: 15.336

3.  Multicomponent reactions for de novo synthesis of BODIPY probes: in vivo imaging of phagocytic macrophages.

Authors:  Ana Vázquez-Romero; Nicola Kielland; María J Arévalo; Sara Preciado; Richard J Mellanby; Yi Feng; Rodolfo Lavilla; Marc Vendrell
Journal:  J Am Chem Soc       Date:  2013-10-16       Impact factor: 15.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.